drugset / Trial / NCT04989803
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
NaSequentialOpen-labelTreatment
Summary
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Timeline
- Start
- 2021-10-27
- Primary completion
- 2030-02
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KITE-363 | Cell therapy | — | Intravenous |
| Subject | KITE-753 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |